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Background: Despite the progress in endovascular treatment for peripheral artery disease (PAD), the long-term patency rate is still suboptimal, 
particularly for diabetic patients. Atherosclerotic plaque characteristics may be predictive of future events in patients with PAD; however, 
morphological plaque features and biomarkers for the risk stratification have not been reported.
Methods: The current study was conducted as part of the DEFINITIVE LE study, where excised plaque using the SilverHawk® Peripheral Plaque 
Excision Systems (Covidien/ev3, Plymouth, MN) from 113 de novo lesions located in the superficial femoral artery of 92 patients with claudication 
(diabetic=46, 50%) were evaluated. Immunohistochemistry was performed for macrophages (CD68, CD163, CD206), T-lymphocytes (CD3), HLA-DR, 
red blood cells (glycophorin A), endothelial cells (ulex), smooth muscle cells (HHF), Toll-like receptor 4, RAGE and ENRAGE, which were all graded 
semi-quantitatively with a blinded manner. RNA and protein profiling were performed in randomly selected 40 cases where a total of 90 genes and 
15 proteins were evaluated.
Results: Primary patency rate at 6 months as assessed by duplex did not differ significantly between diabetic and non-diabetics (84% vs. 74%, 
p=0.37) where lesion pathology and inflammatory markers were also similar between the groups. In contrast, the presence of lesional thrombi 
(n=27, 29%) was significantly associated with a lower patency rate as compared to non-thrombotic lesions (61% vs. 85%, p=0.04). Patients with 
thrombus had higher CD163, HLA-DR, and glycophorin A expression than those without thrombus (p=0.01, p=0.02 and p=0.01, respectively). 
Thrombotic cases also showed increased expression of select inflammatory genes with fold change >2 such as IL-6, IL-8 and chemokines (CXCL1, 2, 
3, and CCL13) as well as increased levels of inflammatory proteins including IL-6 and IL-8.
Conclusions: The presence of lesional thrombi in plaque excision specimens was associated with a significant decrease in patency at 6 months 
with increased expression of several inflammatory markers, suggesting that recognition of thrombi may warrant more attentive follow-up in patients 
with PAD.
